<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Anticoagulant citrate dextrose: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Anticoagulant citrate dextrose: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Anticoagulant citrate dextrose: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F49163836"><span class="drugH1">Brand Names: US</span>
<ul>
<li>ACD Formula A;</li>
<li>ACD-A noClot-50</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46444004"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anticoagulant</li></ul></div>
<div class="block doa drugH1Div" id="F56573958"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5094b0ba-1589-48bf-9983-2ddea6e28ec9">Regional anticoagulation for continuous renal replacement therapy circuit</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Regional anticoagulation for continuous renal replacement therapy circuit (off-label use): Note:</b> Citrate solution must only be prescribed and administered by trained personnel, as standardized (and often specialized) dialysate and/or replacement fluids and titration and monitoring protocols are required (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25018916','lexi-content-ref-24993448']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25018916','lexi-content-ref-24993448'])">Ref</a></span>). Citrate solution is administered through the inflow (prefilter or “arterial”) limb of the extracorporeal CRRT circuit, <b>not</b> administered directly to the patient (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.1'])">Ref</a></span>). <b>Safety: </b>Use is generally considered contraindicated in patients likely to have impaired citrate clearance (eg, acute liver failure with transaminases &gt;1,000 units/L); however, if necessary, may be used with close monitoring and appropriate adjustments (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.1','lexi-content-ref-29324487','lexi-content-ref-35373034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.1','lexi-content-ref-29324487','lexi-content-ref-35373034'])">Ref</a></span>). When regional citrate anticoagulation is utilized, calcium is lost in the dialysis effluent in the form of citrate-calcium complexes. Calcium repletion must be administered to avoid hypocalcemia. Calcium may be infused at the end of the dialysis circuit or IV through a separate central line (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davenport.1','lexi-content-ref-29151020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davenport.1','lexi-content-ref-29151020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Example regimen: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial infusion rate (</i>
<b>
<i>in mL/hour</i></b>
<i>):</i>
<b>Intracircuit:</b> Use ACD-A solution: <b>Approximate usual initial infusion rate:</b> ~1.5 to 1.8 times the blood flow rate; for example, if blood flow rate is 100 to 200 mL/minute, start ACD-A infusion at 150 to 360 mL/<b>hour </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19690224','lexi-content-ref-27866200','lexi-content-ref-24811309','lexi-content-ref-14989634']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19690224','lexi-content-ref-27866200','lexi-content-ref-24811309','lexi-content-ref-14989634'])">Ref</a></span>). Optimal ACD-A regimens have not been identified; refer to institutional protocols as variations exist. Adjustment of ACD-A and calcium infusion rates is dependent on established protocols and ionized calcium concentrations.</p>
<p style="text-indent:-2em;margin-left:6em;">CRRT calcium: Monitor ionized calcium concentrations in outflow (postfilter) limb of the CRRT circuit; maintain CRRT circuit ionized calcium between 1 to 1.4 <b>mg/dL</b> (0.25 to 0.35 <b>mmol/L</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19690224']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19690224'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Serum calcium: Monitor systemic ionized calcium peripherally (drawn directly from the patient), and maintain between 3.6 to 4.8 <b>mg/dL</b> (0.9 to 1.2 <b>mmol/L</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19690224','lexi-content-ref-27866200']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19690224','lexi-content-ref-27866200'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F56983951"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">Not applicable. This product is used in the extracorporeal blood processing with Autologous PRP systems in production of platelet rich plasma (PRP); it is not for direct intravenous infusion.</p></div>
<div class="block coi drugH1Div" id="F46440414"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Direct intravenous infusion</p></div>
<div class="block war drugH1Div" id="F46440415"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: When used for regional anticoagulation of the CRRT circuit: Use with caution in patients with liver impairment. Citrate is partially metabolized by the liver and may accumulate with hepatic impairment leading to toxicity. Considered contraindicated in patients with acute liver failure and blood transaminase values &gt;1,000 units/L; however, if necessary, may be used with close monitoring and appropriate adjustments (Davenport 2021; Meersch 2018; Szamosfalvi 2021).</p>
<p style="text-indent:-2em;margin-left:4em;">• Shock states: When used for regional anticoagulation of the CRRT circuit: Use with caution in patients with shock and hypoperfusion; may accumulate with hypoperfusion/shock states leading to toxicity. Considered contraindicated in patients with cardiogenic shock and blood lactate concentrations &gt;8 mmol/L (Davenport 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not intended for direct intravenous infusion into patients; when used in extracorporeal blood processing for the production of platelet rich plasma, must be used with the Autologous PRP system. Discard if closure system's biological barrier is not intact.</p></div>
<div class="block foc drugH1Div" id="F46440420"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, In Vitro: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ACD Formula A: Citric acid 0.73 g, dextrose monohydrate 2.45 g, and sodium citrate dihydrate 2.2 g per 100 mL (500 mL [DSC], 1000 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">ACD-A noClot-50: Citric acid anhydrous 0.073 g, dextrose monohydrate 0.245 g, and sodium citrate dihydrate 0.22 g per 10 mL (50 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Citric acid monohydrate 0.8 g, dextrose monohydrate 2.45 g, and sodium citrate dihydrate 2.2 g per 100 mL (750 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F49163835"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F49483337"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (ACD-A noClot-50 In Vitro)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.73-2.45-2.2 g/100 mL (per mL): $0.75</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52872154"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, In Vitro: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Citric acid 0.73 g, dextrose monohydrate 2.45 g, and sodium citrate dihydrate 2.2 g per 100 mL (500 mL, 1000 mL)</p></div>
<div class="block use drugH1Div" id="F46440413"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">Anticoagulant used in the extracorporeal blood processing with Autologous PRP systems in production of platelet rich plasma</p></div>
<div class="block off-label drugH1Div" id="F56573956"><span class="drugH1">Use: Off-Label: Adult</span><p>Regional anticoagulation for continuous renal replacement therapy circuit</p></div>
<div class="block mst drugH1Div" id="F50812614"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Anticoagulant citrate dextrose may be confused with anticoagulant sodium citrate</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46283922"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F46283919"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block mop drugH1Div" id="F56573959"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">When used for regional anticoagulation of the CRRT circuit: Monitor serum electrolytes ~15 minutes and 1 hour after starting CRRT, then at least every 6 hours for CRRT; particularly monitor ionized calcium, sodium, potassium, chloride, magnesium, and bicarbonate to avoid metabolic abnormalities; acid-base balance; anion gap; for CRRT, monitor total body calcium at least once daily to calculate the calcium ratio (total calcium/ionized calcium) (calcium ratio may indicate citrate toxicity if &gt;2.1); monitoring postfilter ionized calcium may be beneficial to ensure adequate anticoagulation of the dialysis circuit (Davenport 2021; KDIGO 2012).</p>
<p style="text-indent:-2em;margin-left:2em;">Citrate accumulation may be managed by decreasing the blood flow rate (which decreases citrate requirements), increasing the dialysate rate (CVVHD) or the filtration rate (CVVH) to increase removal, or decreasing the targeted citrate concentration within the filter (Schneider 2017).</p></div>
<div class="block pha drugH1Div" id="F56573957"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Citrate ions induce anticoagulation by chelating free ionized calcium, making it unavailable for use in the coagulation system.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58212893"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Anticoagulation</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Citra.1">
<a name="Citra.1"></a>ACD-A (anticoagulant citrate dextrose) [prescribing information]. Braintree, MA: Citra Labs; February 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19690224">
<a name="19690224"></a>Burry LD, Tung DD, Hallett D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. <i>Ann Pharmacother</i>. 2009;43(9):1419-1425. doi:10.1345/aph.1M182<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/19690224/pubmed" id="19690224" target="_blank">19690224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Davenport.1">
<a name="Davenport.1"></a>Davenport A. Anticoagulation for continuous kidney replacement therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 27, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14712429">
<a name="14712429"></a>Gupta M, Wadhwa NK, Bukovsky R. Regional citrate anticoagulation for continuous venovenous hemodiafiltration using calcium-containing dialysate. <i>Am J Kidney Dis</i>. 2004;43(1):67-73. doi:10.1053/j.ajkd.2003.09.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/14712429/pubmed" id="14712429" target="_blank">14712429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018916">
<a name="25018916"></a>Kidney Disease: Improving Global Outcomes (KDIGO). Summary of recommendation statements. <i>Kidney Int Suppl (2011)</i>. 2012;2(1):8-12. doi:10.1038/kisup.2012.7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/25018916/pubmed" id="25018916" target="_blank">25018916</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27866200">
<a name="27866200"></a>Kirwan CJ, Hutchison R, Ghabina S, et al. Implementation of a simplified regional citrate anticoagulation protocol for post-dilution continuous hemofiltration using a bicarbonate buffered, calcium containing replacement solution. <i>Blood Purif</i>. 2016;42(4):349-355. doi:10.1159/000452755<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/27866200/pubmed" id="27866200" target="_blank">27866200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29324487">
<a name="29324487"></a>Meersch M, Zarbock A. Renal replacement therapy in critically ill patients: who, when, why, and how. <i>Curr Opin Anaesthesiol</i>. 2018;31(2):151-157. doi:10.1097/ACO.0000000000000564<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/29324487/pubmed" id="29324487" target="_blank">29324487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24993448">
<a name="24993448"></a>Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. <i>Clin J Am Soc Nephrol</i>. 2014;9(12):2173-2188. doi:10.2215/CJN.01280214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/24993448/pubmed" id="24993448" target="_blank">24993448</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24811309">
<a name="24811309"></a>Ong SC, Wille KM, Speer R, Tolwani AJ. A continuous veno-venous hemofiltration protocol with anticoagulant citrate dextrose formula A and a calcium-containing replacement fluid. <i>Int J Artif Organs</i>. 2014;37(6):499-502. doi:10.5301/ijao.5000323<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/24811309/pubmed" id="24811309" target="_blank">24811309</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29151020">
<a name="29151020"></a>Schneider AG, Journois D, Rimmelé T. Complications of regional citrate anticoagulation: accumulation or overload? <i>Crit Care</i>. 2017;21(1):281. doi:10.1186/s13054-017-1880-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/29151020/pubmed" id="29151020" target="_blank">29151020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14989634">
<a name="14989634"></a>Swartz R, Pasko D, O'Toole J, Starmann B. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. <i>Clin Nephrol</i>. 2004;61(2):134-143. doi:10.5414/cnp61134<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/14989634/pubmed" id="14989634" target="_blank">14989634</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35373034">
<a name="35373034"></a>Szamosfalvi B , Puri V, Sohaney R, et al. Regional citrate anticoagulation protocol for patients with presumed absent citrate metabolism. <i>Kidney360</i>. 2021;2(2)192-204. doi:10.34067/KID.0005342020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/anticoagulant-citrate-dextrose-drug-information/abstract-text/35373034/pubmed" id="35373034" target="_blank">35373034</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107876 Version 33.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
